Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Kellie Nazemi"'
Autor:
Sabine Mueller, Mariam Aboian, Kellie Nazemi, Karen Gauvain, Janet Yoon, Jane Minturn, Sarah Leary, Mohamed AbdelBaki, Stewart Goldman, Jennifer Elster, Adam Resnick, Annette Molinaro, Joanna Phillips, Michael Prados, Daphne Haas-Kogan
Publikováno v:
Neuro Oncol
OBJECTIVE To estimate the 6-month Progression Free Survival (PFS6) associated with everolimus for progressive/recurrent pLGGs and to determine if activated PI3K/Akt/mTOR pathway as measured by positive phosphorylated-ribosomal protein S6 (p-RPS6) sta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78f97751a7f0c6a97ec3fa538d3f1609
https://europepmc.org/articles/PMC7651691/
https://europepmc.org/articles/PMC7651691/
Autor:
Wendy B. London, Mitali Basu, Tomoyuki Mizuno, Sanjay P. Prabhu, Jay B. Pietrantonio, Lianne Greenspan, Jeffrey C. Allen, Stephen P. Hunger, Jennifer Direnzo, Pei Chi Kao, Joseph Destefano, Susan N. Chi, Karen Wright, Alexander A. Vinks, Danielle Cassidy, Xiaopan Yao, Jessica Boklan, Tanya M. Trippett, Cynthia E. Herzog, Kellie Nazemi, Lia Gore, Kenneth J. Cohen, Matthias A. Karajannis, Amy Smith, Howard M. Katzenstein, John P. Perentesis, Russ Geyer, Mark W. Kieran, Debra Schissel
Publikováno v:
Pediatr Blood Cancer
Background To evaluate efficacy, pharmacokinetics (PK) and pharmacodynamics of single-agent everolimus in pediatric patients with radiographically progressive low-grade glioma (LGG). Methods Everolimus was administered at 5 mg/m2 once daily as a tabl
Autor:
Theodore Nicolaides, Christine A. Pratilas, Andrew Morin, A. Banerjee, Kenneth L. Jones, David Samuel, Guisheng Zhao, Bridget Sanford, Karisa C. Schreck, David A. Solomon, Lindsay Kilburn, Kellie Nazemi, Adam Green, Jean M. Mulcahy Levy
Publikováno v:
Neuro Oncol
BACKGROUND While BRAF-targeted therapy can be effective in a subset of patients with glioma, resistance to treatment can emerge over time. The description and validation of mechanisms of resistance in BRAF-mutant glioma are not previously described.
Autor:
Andres M. Salazar, Kaori Okada, Javad Nazarian, Neil D. Almeida, Susan N. Chi, A. Banerjee, Karen Gauvain, Jared Taitt, Stewart Goldman, Annette M. Molinaro, Sabine Mueller, Lisa H. Butterfield, Kellie Nazemi, Nicholas S Whipple, Michael D. Prados, Ryan Gilbert, John R. Crawford, Javier Villanueva-Meyer, Rishi Lulla, Hideho Okada, Erin R Bonner, Takahide Nejo, Payal Watchmaker
Publikováno v:
Neuro Oncol
BACKGROUND Patients with diffuse midline gliomas (DMG), including diffuse intrinsic pontine glioma (DIPG), have dismal outcomes. We previously described the H3.3K27M mutation as a shared neoantigen in HLA-A*02.01+ H3.3K27M+ DMGs. Within the Pacific P
Autor:
Sridevi Yadavili, Lindsay Kilburn, John R. Crawford, Alison Roos, Eshini Panditharatna, Madhuri Kambhampati, Bo Zhang, Sabine Mueller, Javad Nazarian, Michael E. Berens, Suresh N. Magge, Sara A. Byron, Payal Jain, Adam C. Resnick, Roger J. Packer, Cassie Kline, Yuankun Zhu, Kellie Nazemi, Winnie S. Liang, Xiaodong Yang, Michael D. Prados, David A. Solomon, Anu Banerjee, Annette M. Molinaro, Nalin Gupta, Joanna Philips, John G. Kuhn
Publikováno v:
Neuro-Oncology. 21:ii85-ii85
BACKGROUND: Diffuse intrinsic pontine glioma (DIPG) is an infiltrative, inoperable midline tumor with devastating outcomes. We have recently completed a prospective clinical trial for children and young adults with newly diagnosed DIPG that included